Have Eli Lilly's successes translated into stock performance?Eli Lilly's (NYSE: LLY) broad portfolio of drugs has helped the company's earnings climb over the years -- and in recent times, two products in particular have supercharged growth. The big pharma company sells Mounjaro and Zepbound, both prescribed for weight loss, and demand has been surpassing supply.Pharmaceutical companies are generally viewed as safe investments -- due to people needing their medications no matter what the economy is doing. T ...